Image

Global Dupuytren’s Disease Market - Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Feb 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Dupuytren’s Disease Market, By Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others), Diagnosis (Physical Examination, X-Ray, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Dupuytren’s Disease Market

Market Analysis and Insights Global Dupuytren’s Disease Market

Dupuytren’s disease market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 4.60% in the above mentioned forecast period.

Dupuytren's disease is a malformation of the hand that often develops over time. A layer of tissue beneath the skin of your palm is affected by the illness. The fingers become permanently bent in a flexed position in severe cases. The ring finger is the most commonly affected by Dupuytren's contracture, followed by the little and middle fingers. Alcoholism, smoking, thyroid disorders, liver disease, diabetes, past hand injuries, epilepsy, and family history are all risk factors for Dupuytren's contracture. This condition is also termed as Dupuytren's contracture, familial palmar fibromatosis, and contraction of palmar fascia.

The rise in the prevalence of Dupuytren’s disease will act as major market driver and further enhance the market’s growth rate. Another significant factor influencing the growth rate of Dupuytren’s disease market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, rising initiatives by public and private organisations to spread awareness about disease and growing government funding are the factors that will expand the Dupuytren’s disease market. Other factors such as rising incidences of diabetes and growing geriatric population will positively impact the Dupuytren’s disease market’s growth rate. Additionally, high consumption of alcohol and smoking tobacco will result in the expansion of Dupuytren’s disease market. Increase in the level of disposable income, growing screening and rising risk factors are the major drivers that will propel the market’s growth rate. 

Moreover, the rise in the research and development activities and emerging new market will provide beneficial opportunities for the Dupuytren’s disease market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate Dupuytren’s disease market in future.

However, high cost associated with the surgery and lack of infrastructure in low-income countries will impede the growth rate of Dupuytren’s disease market. Less awareness and complications as well as risk involved with the surgery will further challenge the market in the forecast period mentioned above. Invasive nature of surgery and regression of disease even after treatment are the major market restrains that will further derail the market’s growth rate.

This Dupuytren’s disease market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Dupuytren’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Dupuytren’s Disease Market Scope and Market Size

The Dupuytren’s disease market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of treatment, the Dupuytren’s disease market is segmented into surgery, radiation therapy, needle aponeurotomy, steroid shot, enzyme injection, occupational therapy and others.
  • On the basis of diagnosis, the Dupuytren’s disease market is segmented into physical examination, x-ray and others.
  • On the basis of dosage, the Dupuytren’s disease market is segmented into injection, tablets, and others.
  • On the basis of route of administration, the Dupuytren’s disease market is segmented into oral, parenteral and others.
  • On the basis of end-users, the Dupuytren’s disease market is segmented into clinic, hospital and others.

The Dupuytren’s disease market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Dupuytren’s Disease Market Country Level Analysis

The Dupuytren’s disease market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end-users and distribution channel.

The countries covered in the Dupuytren’s disease market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the Dupuytren’s disease market due to the presence of major key players and high prevalence rate in this region. Additionally, growing geriatric population and well-developed healthcare infrastructure are the major drivers that will flourish the growth rate of Dupuytren’s disease market in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Dupuytren’s disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Dupuytren’s Disease Market Share Analysis

Dupuytren’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Dupuytren’s disease market research.

Some of the major players operating in the Dupuytren’s disease market are Merck & Co., Inc., Fresenius Kabi AG, Bristol-Myers Squibb Company, Endo International plc, Pfizer Inc., Hikma Pharmaceuticals PLC, Spear Pharmaceuticals., Actiza Pharmaceutical Private Limited, Nantong Jinghua Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Abbott, Bayer AG, AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., LEO Pharma A/S, Sumitomo Dainippon Pharma Co., Ltd., Novartis AG, Sanofi, Aurobindo Pharma, and Lupin, among others.

Customization Available : Global Dupuytren’s Disease Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

Dupuytren’s Disease Market is growing at a CAGR of 4.60% during the forecast period of 2022 to 2029.
Global Dupuytren’s Disease Market segmented By Application such as Clinic, Hospital, Others.
This Dupuytren’s disease market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.
The major players operating in the Dupuytren’s disease market are Merck & Co., Inc., Fresenius Kabi AG, Bristol-Myers Squibb Company, Endo International plc, Pfizer Inc., Hikma Pharmaceuticals PLC, Spear Pharmaceuticals., Actiza Pharmaceutical Private Limited, Nantong Jinghua Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Abbott, Bayer AG, AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., LEO Pharma A/S, Sumitomo Dainippon Pharma Co., Ltd., Novartis AG, Sanofi, Aurobindo Pharma, and Lupin, among others.